Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma

Molecular Oncology

Volumn 10, Issue 5, 2016, Pages 751-763

  Rasmussen, Rikke D ^a   Gajjar, Madhavsai K ^a   Jensen, Kamilla E ^a   Hamerlik, Petra ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

DNA repair; Genotoxic stress; Glioblastoma; Olaparib; SAHA

Indexed keywords

DNA; HISTONE DEACETYLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; VORINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EC50; ENZYME INHIBITION; FLOW CYTOMETRY; GENE TARGETING; GLIOBLASTOMA; HOMOLOGOUS RECOMBINATION; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BRAIN; BRAIN NEOPLASMS; COMBINATION DRUG THERAPY; DNA REPAIR; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA REPAIR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLIOBLASTOMA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; PHTHALAZINES; PIPERAZINES; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84955285948     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.12.014     Document Type: Article

References (44)

1. Auffinger B., Spencer D., Pytel P., Ahmed A.U., Lesniak M.S. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev. Neurother. 2015, 15:741-752.
2. Bartkova J., Hamerlik P., Stockhausen M.T., Ehrmann J., Hlobilkova A., Laursen H., Kalita O., Kolar Z., Poulsen H.S., Broholm H., Lukas J., Bartek J. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010, 29:5095-5102.
3. Boyle G.M., Martyn A.C., Parsons P.G. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res. 2005, 18:160-166.
4. Certo M.T., Ryu B.Y., Annis J.E., Garibov M., Jarjour J., Rawlings D.J., Scharenberg A.M. Tracking genome engineering outcome at individual DNA breakpoints. Nat. Methods 2011, 8:671-676.
5. Chamberlain M.C. Radiographic patterns of relapse in glioblastoma. J. Neurooncol. 2011, 101:319-323.
6. Chen J., McKay R.M., Parada L.F. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012, 149:36-47.
7. Cornago M., Garcia-Alberich C., Blasco-Angulo N., Vall-Llaura N., Nager M., Herreros J., Comella J.X., Sanchis D., Llovera M. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis. 2014, 5:e1435.
8. Dungey F.A., Caldecott K.W., Chalmers A.J. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol. Cancer Ther. 2009, 8:2243-2254.
9. Dungey F.A., Loser D.A., Chalmers A.J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:1188-1197.
10. Eyupoglu I.Y., Hahnen E., Buslei R., Siebzehnrubl F.A., Savaskan N.E., Luders M., Trankle C., Wick W., Weller M., Fahlbusch R., Blumcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J. Neurochem. 2005, 93:992-999.
11. Galanis E., Jaeckle K.A., Maurer M.J., Reid J.M., Ames M.M., Hardwick J.S., Reilly J.F., Loboda A., Nebozhyn M., Fantin V.R., Richon V.M., Scheithauer B., Giannini C., Flynn P.J., Moore D.F., Zwiebel J., Buckner J.C. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 2009, 27:2052-2058.
12. Graff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., Fass D.M., Kao P.F., Kahn M., Su S.C., Samiei A., Joseph N., Haggarty S.J., Delalle I., Tsai L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
13. Groth A., Corpet A., Cook A.J., Roche D., Bartek J., Lukas J., Almouzni G. Regulation of replication fork progression through histone supply and demand. Science 2007, 318:1928-1931.
14. Ha K., Fiskus W., Choi D.S., Bhaskara S., Cerchietti L., Devaraj S.G., Shah B., Sharma S., Chang J.C., Melnick A.M., Hiebert S., Bhalla K.N. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014, 5:5637-5650.
15. Hanson J.E., La H., Plise E., Chen Y.H., Ding X., Hanania T., Sabath E.V., Alexandrov V., Brunner D., Leahy E., Steiner P., Liu L., Scearce-Levie K., Zhou Q. SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One 2013, 8:e69964.
16. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2041-2046.
17. Huse J.T., Phillips H.S., Brennan C.W. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59:1190-1199.
18. Jain S., Zain J., O'Connor O. Novel therapeutic agents for cutaneous T-cell lymphoma. J. Hematol. Oncol. 2012, 5:24.
19. Kachhap S.K., Rosmus N., Collis S.J., Kortenhorst M.S., Wissing M.D., Hedayati M., Shabbeer S., Mendonca J., Deangelis J., Marchionni L., Lin J., Hoti N., Nortier J.W., DeWeese T.L., Hammers H., Carducci M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 2010, 5:e11208.
20. Komatsu N., Kawamata N., Takeuchi S., Yin D., Chien W., Miller C.W., Koeffler H.P. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol. Rep. 2006, 15:187-191.
21. Konstantinopoulos P.A., Wilson A.J., Saskowski J., Wass E., Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol. Oncol. 2014, 133:599-606.
22. Krajewska M., Fehrmann R.S., Schoonen P.M., Labib S., de Vries E.G., Franke L., van Vugt M.A. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene 2015, 34:3474-3481.
23. Lord C.J., Tutt A.N., Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 2015, 66:455-470.
24. Lucio-Eterovic A.K., Cortez M.A., Valera E.T., Motta F.J., Queiroz R.G., Machado H.R., Carlotti C.G., Neder L., Scrideli C.A., Tone L.G. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008, 8:243.
25. Mendes-Pereira A.M., Martin S.A., Brough R., McCarthy A., Taylor J.R., Kim J.S., Waldman T., Lord C.J., Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1:315-322.
26. Min A., Im S.A., Kim D.K., Song S.H., Kim H.J., Lee K.H., Kim T.Y., Han S.W., Oh D.Y., Kim T.Y., O'Connor M.J., Bang Y.J. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res. 2015, 17:33.
27. Olive P.L., Wlodek D., Durand R.E., Banath J.P. Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp. Cell Res. 1992, 198:259-267.
28. Park J.H., Kim S.H., Choi M.C., Lee J., Oh D.Y., Im S.A., Bang Y.J., Kim T.Y. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 2008, 368:318-322.
29. Petruccelli L.A., Dupere-Richer D., Pettersson F., Retrouvey H., Skoulikas S., Miller W.H. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 2011, 6:e20987.
30. Rasheed W.K., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs 2007, 16:659-678.
31. Rigakos G., Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012, 17:956-962.
32. Rivera M., Wu Q., Hamerlik P., Hjelmeland A.B., Bao S., Rich J.N. Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma. Cell Death Dis. 2015, 6:e1732.
33. Singh M.M., Johnson B., Venkatarayan A., Flores E.R., Zhang J., Su X., Barton M., Lang F., Chandra J. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro Oncol. 2015, 17:1463-1473.
34. Singh M.M., Manton C.A., Bhat K.P., Tsai W.W., Aldape K., Barton M.C., Chandra J. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol. 2011, 13:894-903.
35. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-191.
36. Squatrito M., Brennan C.W., Helmy K., Huse J.T., Petrini J.H., Holland E.C. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 2010, 18:619-629.
37. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
38. Tanaka S., Louis D.N., Curry W.T., Batchelor T.T., Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat. Rev. Clin. Oncol. 2013, 10:14-26.
39. Tu W.Z., Li B., Huang B., Wang Y., Liu X.D., Guan H., Zhang S.M., Tang Y., Rang W.Q., Zhou P.K. gammaH2AX foci formation in the absence of DNA damage: mitotic H2AX phosphorylation is mediated by the DNA-PKcs/CHK2 pathway. FEBS Lett. 2013, 587:3437-3443.
40. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 2004, 4:814-819.
41. Venere M., Hamerlik P., Wu Q., Rasmussen R.D., Song L.A., Vasanji A., Tenley N., Flavahan W.A., Hjelmeland A.B., Bartek J., Rich J.N. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014, 21:258-269.
42. Wu J., Lu L.Y., Yu X. The role of BRCA1 in DNA damage response. Protein Cell 2010, 1:117-123.
43. Xu J., Sampath D., Lang F.F., Prabhu S., Rao G., Fuller G.N., Liu Y., Puduvalli V.K. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J. Neurooncol. 2011, 105:241-251.
44. Yin D., Ong J.M., Hu J., Desmond J.C., Kawamata N., Konda B.M., Black K.L., Koeffler H.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin. Cancer Res. 2007, 13:1045-1052.